Delivery Order SPE2DB20D1100-SPE2DB25FE1PL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $9,967.07. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 8, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Rexulti 0.5 mg tablets in a 30-count package. This firm fixed-price delivery order, valued at $3,904.92, is scheduled for completion by September 10, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $3,299.21. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 28, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $9,482.33. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 1, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,846.60 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,697.80 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $74,612.17. This non-competitive delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Rexulti (brexpiprazole) 0.5 mg tablets in quantities of 30, with a ceiling value of $1,536.46. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is set for ultimate completion on July 15, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1PLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $27,653.67. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competitive procurement. The ultimate completion date is set for September 30, 2025, and the place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion vehicle designated SPE2DX that extends through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Rexulti (brexpiprazole) is a psychiatric medication used in the treatment of schizophrenia and major depressive disorder, reflecting the company's role in delivering specialty medications across multiple therapeutic domains to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.7k | 9/29/25 |